OLMA

Olema Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company based in San Francisco that develops targeted therapies for women's cancers, especially breast cancer. Its lead drug candidate, palazestrant (OP-1250), is an oral pill designed to block the estrogen receptor that fuels many breast tumors, offering patients a daily-at-home option instead of an injection. Founded in 2016, the company went public in 2020 to fund its clinical trials.